Achiko reports an EBITDA loss of USD $1.9 million, compared to an EBITDA loss of USD $4.6 million for the six months ending June 30, 2021.Focal points of.
Company Provides Novel Solution for Covid-19 Testing Gap with AptameX™, its Highly Effective and Low-Cost DNA Aptamer-Based Technology for the Detection of.
Achiko Establishes Joint Venture with PT Indonesia Farma Medis for Production and Distribution of its Test Platform for Covid-19 in Indonesia
February 12, 2021 07:30 ET | Source: Achiko AG Achiko AG Zurich, SWITZERLAND
Achiko Signs Agreement with PT Indonesia Farma Medis to Establish a New Joint Venture, including a Contract with PT Mitra Asa Pratama and a Memorandum of Understanding with PT Pharos Indonesia, Completion Subject to Formal Approvals
Test Kits Will Be Integrated with Achiko’s Teman Sehat (Health Buddy) Mobile App to Address Growing Demand for Covid-19 Testing in Indonesia
The Joint Venture and the Contracts are a Precursor to Product Registration, Currently Planned to be Filed in the Next Few Weeks